Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100739
C. Carcopino , E. Erdogan , M. Henrich , S. Kobold
Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer. However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression within the tumor microenvironment. This review explores the potential of armored CAR-T cells, or ‘micropharmacies’, in overcoming these obstacles and enhancing the therapeutic outcomes of adoptive T-cell (ATC) therapy. We delve into the engineering strategies behind these advanced therapies and the mechanisms through which they improve CAR-T-cell efficacy. Additionally, we discuss the latest advancements and research findings in the field, providing a comprehensive understanding of the role of armored CAR-T cells in cancer treatment. Ultimately, this review highlights the promising future of integrating micropharmacies into ATC therapy, paving the way for more effective and targeted cancer treatments.
{"title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","authors":"C. Carcopino , E. Erdogan , M. Henrich , S. Kobold","doi":"10.1016/j.iotech.2024.100739","DOIUrl":"10.1016/j.iotech.2024.100739","url":null,"abstract":"<div><div>Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer. However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression within the tumor microenvironment. This review explores the potential of armored CAR-T cells, or ‘micropharmacies’, in overcoming these obstacles and enhancing the therapeutic outcomes of adoptive T-cell (ATC) therapy. We delve into the engineering strategies behind these advanced therapies and the mechanisms through which they improve CAR-T-cell efficacy. Additionally, we discuss the latest advancements and research findings in the field, providing a comprehensive understanding of the role of armored CAR-T cells in cancer treatment. Ultimately, this review highlights the promising future of integrating micropharmacies into ATC therapy, paving the way for more effective and targeted cancer treatments.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100739"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100728
D. König , B. Kasenda , M. Sandholzer , A. Chirindel , A. Zingg , R. Ritschard , H. Thut , K. Glatz , E.A. Kappos , D. Schaefer , C. Kettelhack , J. Passweg , K. Baur , A. Holbro , A. Buser , D. Lardinois , L.T. Jeker , N. Khanna , F. Stenner , M.S. Matter , H. Läubli
Background
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not limited to melanoma patients. Many patients are refractory to TIL-ACT, however, or their cancer becomes resistant. Combining anti-programmed cell death protein 1 (anti-PD-1) with TIL-ACT to antagonize the immunosuppressive tumor microenvironment may synergize to enhance the antitumor potential.
Material and methods
We set up the BaseTIL trial (NCT04165967), a single-center investigator-initiated phase I trial, to test feasibility and safety of TIL-ACT followed by PD-1 blockade in patients with advanced cutaneous melanoma with disease progression after at least one line of anti-PD-1. TIL-ACT included tumor collection, ex vivo TIL expansion, lymphodepletion with cyclophosphamide and fludarabine, TIL transfer, and in vivo TIL stimulation with interleukin 2 (125 000 IU/kg, 10 days). TIL-ACT was followed by nivolumab treatment for a maximum of 2 years. Nine patients were planned for inclusion.
Results
Between 2020 and 2022, we enrolled 11 patients and 9 underwent a TIL transfer (median transfused cell number: 66.25 × 109). Two patients did not start lymphodepletion. Nine patients received at least 1 dose of interleukin 2 (median number: 10; range, 1-10), seven started nivolumab (median number: 5; range, 2-23). All patients had hematologic adverse events (AEs). Most common non-hematologic AEs were fever and cytokine release syndrome. No nivolumab-associated AEs of ≥ grade 2 occurred. The objective response rate to TIL-ACT was 22% (2/9, 2 partial remission).
Conclusions
TIL-ACT with nivolumab is feasible and safe. Larger trials are needed to further determine the efficacy of this combination.
{"title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma","authors":"D. König , B. Kasenda , M. Sandholzer , A. Chirindel , A. Zingg , R. Ritschard , H. Thut , K. Glatz , E.A. Kappos , D. Schaefer , C. Kettelhack , J. Passweg , K. Baur , A. Holbro , A. Buser , D. Lardinois , L.T. Jeker , N. Khanna , F. Stenner , M.S. Matter , H. Läubli","doi":"10.1016/j.iotech.2024.100728","DOIUrl":"10.1016/j.iotech.2024.100728","url":null,"abstract":"<div><h3>Background</h3><div>Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not limited to melanoma patients. Many patients are refractory to TIL-ACT, however, or their cancer becomes resistant. Combining anti-programmed cell death protein 1 (anti-PD-1) with TIL-ACT to antagonize the immunosuppressive tumor microenvironment may synergize to enhance the antitumor potential.</div></div><div><h3>Material and methods</h3><div>We set up the <em>BaseTIL</em> trial (NCT04165967), a single-center investigator-initiated phase I trial, to test feasibility and safety of TIL-ACT followed by PD-1 blockade in patients with advanced cutaneous melanoma with disease progression after at least one line of anti-PD-1. TIL-ACT included tumor collection, <em>ex vivo</em> TIL expansion, lymphodepletion with cyclophosphamide and fludarabine, TIL transfer, and <em>in vivo</em> TIL stimulation with interleukin 2 (125 000 IU/kg, 10 days). TIL-ACT was followed by nivolumab treatment for a maximum of 2 years. Nine patients were planned for inclusion.</div></div><div><h3>Results</h3><div>Between 2020 and 2022, we enrolled 11 patients and 9 underwent a TIL transfer (median transfused cell number: 66.25 × 10<sup>9</sup>). Two patients did not start lymphodepletion. Nine patients received at least 1 dose of interleukin 2 (median number: 10; range, 1-10), seven started nivolumab (median number: 5; range, 2-23). All patients had hematologic adverse events (AEs). Most common non-hematologic AEs were fever and cytokine release syndrome. No nivolumab-associated AEs of ≥ grade 2 occurred. The objective response rate to TIL-ACT was 22% (2/9, 2 partial remission).</div></div><div><h3>Conclusions</h3><div>TIL-ACT with nivolumab is feasible and safe. Larger trials are needed to further determine the efficacy of this combination.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100728"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100812
E. Speziale , L. Brunetti , V. Santo , M.G. Tucci , F. Spagnolo , R. Giusti , M. De Tursi , P. Queirolo , F. Zoratto , D.J. Pinato , M.G. Vitale , A. Inno , R. Chiari , R. Marconcini , M. Ghidini , S. Bracarda , A.J. Gelibter , F. Grossi , P.A. Ascierto , A. Cortellini
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100918
L. Liguori , G. Polcaro , V. Manzo , V. Pagliara , C. Ferrone , G. Cattaneo , E. Debellis , M. Cascella , A. Filippelli , V. Conti , S. Pepe , F. Sabbatino
{"title":"36P Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)","authors":"L. Liguori , G. Polcaro , V. Manzo , V. Pagliara , C. Ferrone , G. Cattaneo , E. Debellis , M. Cascella , A. Filippelli , V. Conti , S. Pepe , F. Sabbatino","doi":"10.1016/j.iotech.2024.100918","DOIUrl":"10.1016/j.iotech.2024.100918","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100918"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100861
D. Oh , P. Vu , J.C. Baranda , J. Henry , I.I. Rodriguez Rivera , J.D. Eskew , R. Belani , M. Martinez-Prieto , J. McCaigue , H. Namini , S. Haag , D. Bauer , C. Martin , C. Gregovics , A. Murphy , J. Coronella , D.J. Shedlock , E.E. Dumbrava
{"title":"50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies","authors":"D. Oh , P. Vu , J.C. Baranda , J. Henry , I.I. Rodriguez Rivera , J.D. Eskew , R. Belani , M. Martinez-Prieto , J. McCaigue , H. Namini , S. Haag , D. Bauer , C. Martin , C. Gregovics , A. Murphy , J. Coronella , D.J. Shedlock , E.E. Dumbrava","doi":"10.1016/j.iotech.2024.100861","DOIUrl":"10.1016/j.iotech.2024.100861","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100861"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.101003
G. Chen , C. Zheng , X. Xie , E. Zou , Y. Wang
{"title":"43P Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma","authors":"G. Chen , C. Zheng , X. Xie , E. Zou , Y. Wang","doi":"10.1016/j.iotech.2024.101003","DOIUrl":"10.1016/j.iotech.2024.101003","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101003"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143131923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100810
Z. Song , C. Cai , X. Sun , W. Lao , D. Wang , X. Wang , H. Liu , W. Cui , J. Du , M. Chen , H. Wang
{"title":"67MO Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab in patients with MSS/pMMR locally advanced rectal cancer: A multicentre phase II trial (mRCAT)","authors":"Z. Song , C. Cai , X. Sun , W. Lao , D. Wang , X. Wang , H. Liu , W. Cui , J. Du , M. Chen , H. Wang","doi":"10.1016/j.iotech.2024.100810","DOIUrl":"10.1016/j.iotech.2024.100810","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100810"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号